Our study for the first time explored the PTEN inhibitor BPV as a proangiogenic drug to protect against MI in mice, and this might give us a hint that PTEN inhibitor BPV might serve as a candidate therapeutic drug to treat MI patients in the future. The gene discussed is PTEN; the disease is myocardial infarction.